Illuminare Biotechnologies reported first‑in‑human Phase 1 results for Illuminare‑1, an imaging agent that binds myelin and fluoresces under blue light to reveal peripheral nerves during surgery. The trial showed rapid onset and sustained visualization, addressing a key unmet need: iatrogenic nerve injury that contributes to long‑term morbidity across multiple surgical specialties. Stewart McCallum, Illuminare’s CMO, detailed the agent’s mechanism and early human performance, positioning the compound for broader clinical evaluation in procedures where nerve preservation is critical. Fluorescent nerve mapping is a niche but clinically consequential innovation that could reduce postoperative complications and improve functional outcomes.